Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2010 Aug;12(8):855-9.
doi: 10.1093/ntr/ntq102. Epub 2010 Jun 28.

Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette

Affiliations
Controlled Clinical Trial

Higher nicotine levels in schizophrenia compared with controls after smoking a single cigarette

Jill M Williams et al. Nicotine Tob Res. 2010 Aug.

Abstract

Introduction: The increase in blood nicotine after smoking a single cigarette is nicotine boost. We hypothesized that smokers with schizophrenia (SCZ) have a greater nicotine boost than controls without this disorder.

Methods: Twenty-one subjects (11 SCZ and 10 controls, CON) had repeated venous blood sampling before, during, and after smoking a single cigarette after 12-hr abstinence to measure nicotine concentrations. Blood samples were drawn at baseline (before smoking) and 1, 2, 4, 6, 8, 10, 20, 30, 60, 90, and 120 min after the first puff. Groups were similar in baseline characteristics, including gender and level of dependence, and all smoked 20-30 cigarettes/day. Area under the serum nicotine concentration-time curve (AUC(20)) was calculated for time up to 20 min after the start of smoking.

Results: The mean difference in AUC(20) was significantly greater for SCZ versus CON (135.4 ng-min/ml; 95% CI = 0.45-283.80). The shape of the nicotine concentration-time curve for SCZ was significantly different compared with controls (p < .01). Nicotine boost in the first 4 min of smoking was higher in SCZ versus CON (25.2 vs. 11.1 ng/ml, p < .01) with no difference in the total time spent smoking.

Discussion: This technique improves on methods, which draw only two blood specimens to assess nicotine intake. Understanding how nicotine boost differs in SCZ from CON may explain high levels of addiction and low success in cessation in smokers with SCZ.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Predicted values of SCZ and CON were obtained from the polynomial mixed model analysis with fixed effects (p < .001 for time to the sixth power for both SCZ and CON): y = 11.67 + 0.97 × (time − 29.25) + 0.07 × (time − 29.25)2 − 0.003 × (time − 29.25)3 − 7.01 × 10−05 × (time − 29.25)4 + 2.87 × 10−6 × (time − 29.25)5 − 2.01 × 10−8 × (time − 29.25)6 for SCZ and y = 8.01 + 0.30 × (time − 29.25) + 0.03 × (time − 29.25)2 − 0.001 × (time − 29.25)3 − 3.01 × 10−5 × (time − 29.25)4 + 1.34 × 10−6 × (time − 29.25)5 − 9.17 × 10−8 × (time − 29.25)6 for CON. To minimize extrapolation error due to no measurements between the following intervals, the polynomial curves over these intervals were connected by straight line segments between 10 and 20, 20 and 30, 30 and 60, 60 and 90, and 90 and 120 min.

References

    1. Benowitz NL, Porchet H, Jacob P. Pharmacokinetics, metabolism and pharmacodynamics of nicotine. In: Wonnacott S, Russell MAH, Stolerman IP, editors. Nicotine psychopharmacology: Molecular, cellular, and behavioural aspects. Oxford, UK: Oxford University Press; 1990. pp. 112–157.
    1. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine & Tobacco Research. 2001;3:7–16. - PubMed
    1. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophrenia Research. 2005;76:135–157. - PubMed
    1. Dempsey D, Tutka P, Jacob P, 3rd, Allen F, Schoedel K, Tyndale RF, et al. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology and Therapeutics. 2004;76:64–72. - PubMed
    1. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.

Publication types